In this view, it has been shown that type-1 polarized DCs drive Th1-type immune responses that have the potential to mediate tumor therapy through multiple effectors, such as CD8+ CTLs and Th1-skewed CD4+ T helper cells [33, 34]. Here, CD8A is linked to neoplasm.